British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that alleged Pfizer's respiratory ...
The European Commission approved Pfizer's respiratory syncytial virus vaccine for the prevention of lower respiratory tract ...
Children aged 6 months to 12 years are the main spreaders of respiratory syncytial virus (RSV) infections within their ...
Knowledge of respiratory syncytial virus (RSV) disease and RSV vaccine eligibility is low among hospitalized older adults, ...
Acute respiratory syncytial virus was associated with elevated incidence of cardiovascular events among older adults, ...
Coinfection with RSV, REV, and MPV was significantly associated with treatment failure and prolonged treatment in children with viral LRTIs on respiratory support.
Older adults and people with certain medical conditions are more likely to receive the respiratory syncytial virus (RSV) ...
Pharmaceutical Technology on MSN6d
Pfizer’s RSV vaccine wins expanded approval in EU, gaining edge over GSKAbrysvo is now approved in the EU for adults aged 18 to 59 who are at increased risk of lower respiratory tract disease ...
As the respiratory syncytial virus (RSV) vaccine field grapples with a significantly reduced market size thanks to regulatory ...
Pfizer (PFE) and GSK (GSK) settle RSV vaccine patent lawsuit, dismissing the case with prejudice. REad more here.
Zacks.com on MSN5d
PFE Secures EU Nod for Expanded Use of RSV Vaccine AbrysvoThe latest decision makes Pfizer's Abrysvo the first RSV vaccine approved for use in non-pregnant adults under 50 years of ...
Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has issued a decision amending the marketing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback